In the pipeline: Brentuximab vedotin (SGN-35)

Submitted by Ross Bonander Sun 01/02/2011

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Today's featured lymphoma treatment in the pipeline is the antibody drug conjugate brentuximab vedotin.

Name: Brentuximab vedotin
Class: Antibody drug conjugate (ADC)
Type: Targeted treatment
FDA to date: In Phase II/III trials. FDA approval expected in late 2011.
Manufacturer: Seattle Genetics
Indications: Hodgkin lymphoma, anaplastic large T-cell (non-Hodgkin) lymphoma

SGN

A few words: Brentuximab vedotin is arguably generating more hype and excitement than any other lymphoma treatment in the pipeline right now. it is riding the high of outstanding press following very positive data against both Hodgkin's and ALCL reported at the 2010 American Society of Hematology meeting in December. Most expect Seattle Genetics to receive FDA approval for the treatment sometime in 2011.

Brentuximab vedotin brings together an anti-CD30 monoclonal antibody and the synthetic antimicrotubule agent monomethyl auristatin E (MMAE). Once in the body, the monoclonal antibody acts as a targeting system, seeking out cancer cells and delivering its cytotoxic payload (MMAE) into the malignant cell. Efficacy appears very high with a relatively low toxicity profile.

By Ross Bonander

Click here to see clinical trials involving brentuximab vedotin.

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.